OasisLMS

Join HRS Board Member Prashanthan Sanders, MBBS, PhD, FHRS (University of Adelaide) as he discusses this exciting paper, presented at Heart Rhythm 2025. He is joined in the Heart Rhythm Tv Studio in San Diego, California by Louise Segan, MBBS, MPH (Alfred Health), and Takanori Yamaguchi, MD, PhD (Saga University). This discussion took place on-site at Heart Rhythm 2025.

• Discuss the use of catheter ablation in treating atrial fibrillation in patients with cardiac amyloidosis and sarcoidosis.

Article Authors

Alireza Oraii, Arian Afzalian, Oriol Rodriguez-Queralto, Corentin Chaumont, Adrian Petzl, Jenna Spears, Rahul Myadam, Balaram Krishna J. Hanumanthu, Matthew C. Hyman, Timothy Markman, Poojita Shivamurthy, Ramanan Kumareswaran, Robert D. Schaller, Gregory E. Supple, David S. Frankel, Fermin C. Garcia, Sanjay Dixit, Saman Nazarian, Francis E. Marchlinski

Podcast Contributors

Prashanthan Sanders, MBBS, PhD, FHRS, University of Adelaide
Louise Segan, MBBS, MPH, Alfred Health 
Takanori Yamaguchi, MD, PhD, Saga University

All relevant financial relationships have been mitigated.

Host Disclosure(s):

P. Sanders:
Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical
Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical

​Contributor Disclosure(s):

T. Yamaguchi:
Honoraria/Speaking/Consulting: Abbott Japan, Biotronik, Boston Scientific, Abbott Medical, Japan Medtronic, Inc.,
Daiichi Sankyo, Novartis, Japan Lifeline, Nihon Kohden, Bayer Healthcare Pharmaceuticals Japan, Boehringer Ingelheim

L. Segan:
Nothing to disclose.
 

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
S. Colbert: No relevant financial relationships with ineligible companies to disclose.